CTLA4 and melanoma: Immunotherapy has revolutionized cancer treatment, with ICIs including monoclonal anti‐PD‐1, anti‐PD‐L1, and anti‐CTLA‐4 having significantly improved survival outcomes in lung cancer and melanoma patients.16, 17, 18